An Fc-Competent Anti-Human TIGIT Blocking Antibody Ociperlimab (BGB-A1217) Elicits Strong Immune Responses and Potent Anti-Tumor Efficacy in Pre-Clinical Models

Overview of attention for article published in Frontiers in immunology, February 2022

Altmetric Badge

About this Attention Score

Above-average Attention Score compared to outputs of the same age (63rd percentile)
Good Attention Score compared to outputs of the same age and source (71st percentile)

Mentioned by

twitter: 1 X user

patent: 1 patent

Citations

dimensions_citation: 29 Dimensions

Readers on

mendeley: 33 Mendeley

Summary X Patents Dimensions citations

So far, Altmetric has seen 1 X post from an account with 1,384 followers.

An Fc-Competent Anti-Human TIGIT Blocking Antibody Ociperlimab (BGB-A1217) Elicits Strong Immune Responses and Potent Anti-Tumor Efficacy in Pre-Clinical Models by Xin Chen https://t.co/byktxLolv2

14 Mar 2022

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.